Executive Director, Singapore Translational Cancer Consortium;
Deputy Director & Senior Principal Investigator, Cancer Science Institute of Singapore, NUS;
Provost’s Chair & Professor, Yong Loo Lin School of Medicine, National University of Singapore;
Director, National University Cancer Institute, Singapore (NCIS);
Head and Senior Consultant, Division of Haematology, Department of Haematology-Oncology, NCIS;
Leader, Haematologic Malignancy Tumour Group, NCIS
Profess Chng Wee Joo is the Executive Director of the Singapore Translational Cancer Consortium. He obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. He completed his Fellowship training in haematology in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics.
He is a member of many international professional committees, such as American Society of Haematology Scientific Committee on Plasma Cell Neoplasia, the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials. He has authored more than 200 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his research both locally and internationally including the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award, and the Celgene Future Leaders in Haematology Award.
Professor Chng’s current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.
Prof Lim Soon Thye
Co-Director, Singapore Translational Cancer Consortium; Deputy Group Chief Executive Officer (Research & Education) Singapore Health Services;
Deputy Medical Director (Clinical), National Cancer Centre Singapore;
Senior Associate Dean, MD Programme, Duke-NUS Medical School
Professor Lim Soon Thyegraduated from the National University of Singapore and subsequently obtained his membership with the Royal College of Physician (UK). He received specialist training in medical oncology at the National Cancer Centre Singapore and further training in lymphoid malignancies at the University of Southern California. Currently, he is a senior consultant and deputy medical director (clinical) at NCCS. He also heads Singhealth-DukeNUS Blood Cancer Centre and a regular rank professor at Duke-NUS medical school.
His other leadership roles and positions include serving as the chairman of the Singhealth Central Institutional Review Board-B, director of ACP Oncology Clinical Service, chairman of the cancer service line development and chairman of the national medical oncology residency advisory committee. Additionally, he is also the current associate Dean for Clinical Education at Duke-NUS medical school. Prof Lim previously served as the president of the Singapore Society of Oncology from 2006 to 2010, and chairman of the chapter of Medical Oncologist, Academy of Medicine Singapore from 2010 to 2014. He is an active council member at the Singapore Cancer Society (SCS) where he also chairs the SCS medical professional and audit committee as well as the cancer treatment fund committee.
Prof Lim’s research focus is on lymphoid malignancies; in particular T and NK/T cell lymphomas, that occur more frequently in Asia. He has published more than 100 papers in high impact international journals such as Cancer Cell, Lancet Oncology and Journal of Clinical Oncology. He is the co-founder of the Asian Lymphoma Study Group, which includes academic medical centres across Asia.
Prof Lim was also the Principal Lead Investigator of a Translational and Clinical Research (TCR) Flagship Programme, Large Collaborative Grant (LCG) funded by NMRC (National Lymphoma Translational Research Program: From Genomics to Therapeutics from 2014 to 2019; Singapore lYMPHhoma TranslatiONal studY from 2019-2024).
Additionally, his team leads the blood cancer (T cell lymphoma) genomics project at the International Cancer Genomics Consortium. His group has been successful in securing more than S$20 million of NMRC, industrial and philanthropic funding over the years. His research efforts won him the 3rd Kobayashi Foundation Award in May 2014 in Taipei. This award was created to recognize distinguished research achievements in the field of cancer in Asian countries. Previously, he was also awarded Singhealth Distinguished Young leader Award in 2011. In 2015, he is also conferred the title of Tanoto Professorship in Medical Oncology. More recently, he is also part of an international team that won the American Association of Cancer Research (AACR) Team Science Award. The AACR Team Award is a prestigious award that recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that advances our fundamental knowledge of cancer.
Prof Goh Boon Cher
Platform Lead, Cancer Clinical Trials and IMUs, Singapore Translational Cancer Consortium;
Deputy Director, Cancer Science Institute of Singapore;
Deputy Director, National University Cancer Institute, Singapore (Research);
Senior Consultant, Department of Hematology-Oncology, National University Cancer Institute, Singapore;
Professor, Department of Pharmacology & Department of Medicine, National University of Singapore;
Group Chief, Physician Leadership and Organisation Development Office, National University Health System, Singapore
Professor Goh Boon Cher received his undergraduate medical education at the National University of Singapore, and joined the Department of Hematology-Oncology, NUH where he completed fellowship in medical oncology, and completed a National Medical Research Council fellowship in clinical pharmacology and phase I clinical trials at the University of Chicago. Professor Goh has established himself as a leading clinician scientist in clinical pharmacology and cancer drug development, and currently serves on several institutional and national research portfolios. He has contributed much to the development of a clinical trial research infrastructure at the NCIS, one of the largest clinical research groups in Singapore, and chaired the Cancer Therapeutics Research Group, an Asia Pacific cancer research group. As a clinician, Professor Goh is well established in the fields of head and neck/lung cancer. As a senior clinician and scientist, he has mentored many clinical oncology and pharmacology fellows, and has been awarded senior clinician scientist from the Biomedical Research Council and the National Medical Research Council since 2005. In addition, he has been competitive in being awarded research grants as principal investigator of both individual project grants and infrastructure grants. Beyond cancer therapeutics, he is also widely published in pharmacogenetics, studying how human genetics affect drug response. Internationally, as a key opinion leader, he has served on advisory boards of several pharmaceutical companies advising on drug development of very novel drugs, and has served on editorial boards of important journals like the Journal of Clinical Oncology and Annals of Oncology. As a responsible member of clinical research, he has also espoused principles of ethics, and served for several terms as Chairman of the Domain Specific Research Board.
Platform Lead, Cancer Clinical Trials & IMUs Platform, Singapore Translational Cancer Consortium;
Senior Consultant Medical Oncologist, National Cancer Centre Singapore;
Senior Clinician-Scientist, Genome Institute of Singapore
Assoc. Prof Daniel Tan has a specialist interest in thoracic, head and neck oncology and cancer drug development. His work is focused on addressing the translational gap between basic science and clinical practice – particularly in improving our understanding of the determinants of response and resistance to targeted therapy and immunotherapy.
In recognition of his research, he received the American Society of Clinical Oncology (ASCO) Merit Award twice, an ASCO Young Investigator Award and the SingHealth GCEO Outstanding Clinician-Researcher Award (2016). In 2019, he was awarded the Daniel C. Idhe Lectureship in Medical Oncology from the International Association for Study of Lung Cancer (IASLC) 2019 for his ‘extensive contributions in the lung cancer arena’. He was twice awarded the Clinician-Scientist Award from the National Medical Research Council of Singapore (NMRC). He has published more than 100 peer-reviewed articles, including top tier journals such as The New England Journal of Medicine, The Lancet, Nature, Nature Genetics, Nature Medicine and Journal of Clinical Oncology.
Dr. Tan received undergraduate training at St Bartholomew’s and Royal London Hospitals in the United Kingdom, obtained First Class honours for an Intercalated BSc in Tumor Biology from University College London (UCL), and undertook a postgraduate fellowship in drug development at the Royal Marsden Hospital. In 2017, he completed his PhD in Cancer Biology from Cancer Science Institute, National University of Singapore.
A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer (DT), 2015
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) versus Crizotinib in Patients with ALK-positive Advanced Lung Cancer
An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib (DT), 2015
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive- Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy (Dlim), 2015
A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations, 2016
A Phase Ib/II Multi-centre, Randomized, Open-label Trial to Compare MSC2156119J combined with Gefitinib Versus Chemotherapy as Second Line Treatment in Subjects with MET Positive, Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to First Line Gefitinib, 2013
A phase I, multi-center, open label dose escalation and expansion study of EGFRmut-TKI EGF816, administered orally in adult patients with EGFR-mut solid malignancies, 2014
A Phase Ib open-label clinical trial of once daily oral treatment of afatinib plus weekly intravenous infusion of BI 836845 in patients with EGFR mutant non-small cell lung cancer with progression following prior EGFR tyrosine kinase inhibitors, 2014
Dr Eng Chon Boon
Platform Lead, Cancer Databases & Tissue Banks, Singapore Translational Cancer Consortium Director, NUH Tissue Repository, Research Office, National University Health Systems, Singapore
Dr Eng Chon Boon is the co-lead of the Cancer Databases and Tissues Banks platform of the Singapore Translational Cancer Consortium. He is also the director for the Tissue Repository, National University Hospital (NUH), and runs the Hospital-based Cancer Registry (HCR) at the National University Cancer Institute (NCIS), and has an adjunct position in the Saw Swee Hock School of Public Health (SSHSPH), National University of Singapore (NUS). He is also the principal person-in-charge of tissue banks across the National University Health System (NUHS) public healthcare cluster, and the co-lead PI for the Singapore Integrated Network of Biorepositories (SINB), an infrastructure network formed by academic tissue repositories in Singapore. He is the Singapore’s convenor for ISO//TC276 Biotechnology and in the editorial board of “Biopreservation and Biobanking” by Mary Ann Liebert.
He is a past recipient for International Society for Biological and Environmental Repositories (ISBER) special service award (2010) and had numerous voluntary responsibilities within the ISBER over the years (Councilor, Chair of the ISBER Marketing Committee, members of ISBER Finance, Nominating, Strategic Planning, Program Committee), vice-chair of local organizing committee for the 2007 ISBER Annual Meeting in Singapore. Currently, he is also a member of the advisory panel for Biosample Hub, a not-for-profit company that helps industry requesters to partner with academic providers. He has numerous publications/book chapter/patent in the field of biobanking and had given talks, conducted biobanking workshops and consulted for various international biobanks over the past 15 years.
For a list of biobanking activities and further info, please refer to the following:
Platform Lead, Cancer Databases & Tissue Banks, Singapore Translational Cancer Consortium;
Senior Consultant (Medical Oncology), National Cancer Centre Singapore (NCCS);
Director of Research, Clinical Analytics, Division of Medical Oncology, NCCS, Singhealth;
Senior Clinician Scientist, Genome Institute of Singapore, A*Star
Assoc. Professor Iain Tan is a Senior Consultant Medical Oncologist, leading the colorectal cancer service in the GI Oncology Team at the Department of Medical Oncology, National Cancer Centre Singapore. He co- chairs Singhealth’s multidisciplinary colorectal cancer tumor board. Nationally, he chairs the Medical Oncology Exit Exam committee for specialist accreditation & is a member of MOH’s research training review panel & NMRC’s grant review panel. At NCCS, he is also the clinical chair for NCCS’s luminal GI cancer Comprehensive Research Program. Concurrently, he is a clinician scientist at Genome Institute of Singapore and an assistant professor at Duke-NUS. His research focuses –on metastases and drug resistance and immune-oncology in gastrointestinal cancers, with a special interest in non-invasive diagnostics & innovative early phase clinical trials. He has published widely, with many first or corresponding authorpublications in leading journals including Journal of Clinical Oncology, Nature Medicine, Nature Genetics, Science Translational Medicine and Lancet Oncology. For his research, he has received the ASCO Young Investigator Award (2010) and ASCO Merit Award (2011) and Singhealth Distinguished Young Researcher Award. For his clinical service & research, he received the Singapore Youth Award in 2014, the country’s highest award for youths.
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium;
Director, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-MED);
Deputy Medical Director (Research);
Deputy Director (Global Relations);
Senior Principal Investigator, Institute of Molecular and Cell Biology, Singapore;
Senior Group Leader, Genome Institute of Singapore
Professor Teh Bin Tean obtained his MD (1992) from the University of Queensland, Australia and his PhD (1997) from the Karolinska Institute, Sweden.
Following postdoctoral works at Karolinska Institute, Professor Teh joined the Van Andel Research Institute (VARI), USA in 2000 as a Senior Scientific Investigator heading the Laboratory of Cancer Genetics. In 2007, Professor Teh was appointed as the founding Director of the National Cancer Centre Singapore (NCCS)-VARI laboratory, which serves as a bridge between translational research and clinical medicine. In 2010 he received the Singapore Translational Research Investigator Award (STaR) and relocated to Singapore and is currently a full professor in Cancer and Stem Cell Biology (CSCB) Programme at Duke-NUS. He served as the SingHealth Group Director for Translational Research from 2010-2012.
His laboratory focuses on Genomics of Asian-Prevalent Cancers and in the last 5 years have made seminal discoveries in the field including hepatobiliary cancer, herbal carcinogen-related cancer and fibroepithelial tumors of the breast.
He holds Adjunct Professorships at several universities worldwide including Baylor College of Medicine, USA, Nanjing University and Sun Yat-Sen University, China and the Karolinska Institute, Sweden.
Professor Teh has published extensively, with over 400 publications in high impact scientific journals. He is a past and present member of numerous editorial boards for journals including Science Translational Medicine, Lancet Oncology, Cancer Research, Molecular Cancer Therapeutics, International Journal of Cancer. Professor Teh is a recipient of the 2015 Singapore President Science Award and the 2018 AACR (American Association of Cancer Research) Team Science Award.
Dr Alexander Lezhava
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium;
Senior Group Leader, Translational Research, Genomic Institute of Singapore
Dr Alexander Lezhava assumed the appointment as Group Leader, in the Translational Research group 1 (TR1), at the Genome Institute of Singapore, in August 2013. As a Senior Group Leader, Dr Lezhava, leads TR1 in promoting the smooth transition from basic research to advances in science and technology, and hence to innovation. Mainly focusing on molecular diagnostics, the mission of TR1 is to provide and market molecular diagnostic discoveries aligned with the industry needs and further develop these together with commercial partners.
Dr Lezhava also holds a concurrent appointment as the Program Director of POLARIS (Transforming Disease Management through Personalised Profiling) program since October 2016. He has actively pushed POLARIS to new heights in RIE2020. His key missions are for POLARIS to maintain its CAP accreditation on top of forging closer links with genomic initiatives at A*STAR as well as industry partners. POLARIS has become a supportive platform for clinical decision-making through molecular genomics. It has gradually evolved and is currently fully capable to serve a clinical community across Singapore and SEA region. In addition, Dr Lezhava serves the institute as a Management Representative for ISO accredited research groups for several years. Under his leadership, both TR1 and the New Generation Sequencing groups achieved ISO 13485 accreditation since 2015. This now has further expand with 2 additional research groups.
In response to the recent COVID-19 pandemic, A*STAR was commissioned for a central testing facility, where Dr Lezhava undertook the critical role of Laboratory Director of Stronghold Diagnostic Lab. His many years of experience managing POLARIS paired with his deep knowledge of molecular diagnostics renders him fit for this role.
Finally, Dr Lezhava extends his research network through his assignment as Visiting Professor of Academician of N. Kipshidze Central University Clinic, Tbilisi Georgia since 2008 and Visiting Professor of Clinical Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa, Japan, from 2010 to 2012. This enables the coveted exchange of both students and knowledge which is advantageous and enriching.
Prior to his current appointment, Dr Lezhava was a Research Director with Dx Assays from 2011 to 2013. His other earlier positions were a Senior Scientist followed by a Unit Leader under RIKEN, Japan from 2006 to 2010. He started out as a Senior Researcher with K.K. DNAform, Biotech company in 2002.
Dr Lezhava’s research interest is in Translational research, Molecular Diagnostics, Genomics technology development and he has published as many as 54 research papers, holds 4 patents and 11 technical disclosures. For his outstanding contributions to research, Dr Lezhava has received the Suzuken Memorial Foundation award in 2007 and Letter of Appreciation from President of RIKEN in 2009.
Dr Lezhava graduated with a PhD from the Hiroshima University, Faculty of Engineering, Department of Fermentation Technology and Master of Science from Tbilisi State University, Faculty of Biology, Department of Genetics, in 1996 and 1990 respectively. His philosophy is “Professionalism of the Group is a key for successful activities”. Therefore as a group leader and a Program Director his task is to attract motivated individuals with a strong background from both, industry and academia.
Dr Anand Jeyasekharan
Platform Lead, Translational Research Integration & Support, Singapore Translational Cancer Consortium;
Principal Investigator and Facility Head (Microscopy), Cancer Science Institute of Singapore;
Consultant, Department of Haematology-Oncology, National University Cancer Institute Singapore;
Assistant Professor; Department of Medicine, Yong Loo Lin School of Medicine, NUS;
Assistant Director of Research (Medical Oncology), Department of Haematology-Oncology, National University Health System
Dr Jeyasekharan obtained his undergraduate medical degree from Christian Medical College Vellore, India in 2003. He then completed a PhD in Oncology (2008) under the mentorship of Professor Ashok Venkitaraman at the University of Cambridge UK, on a Gates Cambridge Scholarship. Following a post-doctoral fellowship in Cambridge as a Junior Research Fellow (Wolfson), he joined the National University Hospital Singapore in 2010 to complete his training in Internal Medicine, and Medical Oncology (2016). He has been active in medical research at the National University Health System, and holds a joint appointment at the Cancer Science Institute, where he has run a basic science laboratory since 2013.
Dr Jeyasekharan’s clinical interest is in aggressive B-cell neoplasms, and he is currently a consultant medical oncologist on the National University Hospital lymphoma team. He also serves as the assistant director of research for the division of medical oncology at National University Hospital, and is an active member of the NUHS clinician-scientist unit, where he administers the National University Hospital Clinician-Scientist Program for Residents (NCSP-R).
Mr Seck Yee Kwang
Platform Lead, Business Intelligent & Development Unit, Singapore Translational Cancer Consortium;
Director, Biomedical Sciences Industry Partnership Office, A*Star
Mr Seck Yee Kwang oversees the industry development for the Health & Biomedical and Food & Consumer sectors at the Agency for Science, Technology & Research (A*STAR). He also leads the Biomedical Sciences Industry Partnership Office, overseeing research and innovation partnerships with strategic industry partners across the public sector research, clinical and university institutions.
Translating the research and innovation efforts across A*STAR and the research ecosystem in Singapore to forge impactful and outcome-driven partnerships with industry is his key focus. Mr Se also has a keen interest in understanding the opportunities that future advances in science and technology could bring in disrupting or transforming current industry landscapes, and assessing these opportunities for Singapore.
Prior to joining A*STAR, Yee Kwang spent his earlier years at the Singapore Economic Development Board, in various industry and policy roles. This included a stint at the Human Capital Leadership Institute, where he was Head of Partnership Development.
Yee Kwang has a Bachelor’s and Master’s degree in Electrical Engineering from the University of Illinois at Urbana Champaign, and the University of California, Santa Barbara. His Master’s research focus was on compound semiconductor device modelling. He also obtained a Graduate Certificate of Intellectual Property Law from the IP Academy.